The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Oncogenically active MYD88 mutations in human lymphoma
Open accessAbstract
The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy. Constitutive nuclear factor (NF)-κB and JAK kinase signalling promotes malignant cell survival in these lymphomas, but the genetic basis for this signalling is incompletely understood. Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, and the discovery of highly recurrent oncogenic mutations affecting MYD88 in ABC DLBCL tumours. RNA interference screening revealed that MYD88 and the associated kinases IRAK1 and IRAK4 are essential for ABC DLBCL survival. High-throughput RNA resequencing uncovered MYD88 mutations in ABC DLBCL lines. Notably, 29% of ABC DLBCL tumours harboured the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core. This mutation was rare or absent in other DLBCL subtypes and Burkitt’s lymphoma, but was observed in 9% of mucosa-associated lymphoid tissue lymphomas. At a lower frequency, additional mutations were observed in the MYD88 TIR domain, occurring in both the ABC and germinal centre B-cell-like (GCB) DLBCL subtypes. Survival of ABC DLBCL cells bearing the L265P mutation was sustained by the mutant but not the wild-type MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation. The L265P mutant promoted cell survival by spontaneously assembling a protein complex containing IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signalling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-β. Hence, the MYD88 signalling pathway is integral to the pathogenesis of ABC DLBCL, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MYD88 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Adaptive Immunity by the Innate Immune System
Iwasaki, A., & Medzhitov, R. (2010) · Science · doi:10.1126/science.1183021 · Cited by 2,157
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationHelical Assembly in the MyD88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling
Lin, S.-C., Lo, Y.-C., & Wu, H. (2010) · Nature · doi:10.1038/nature09121 · Cited by 1,111
Davis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Self-citationMutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Compagno, M., Lim, W. K., Grunn, A., Nandula, S. V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., et al. (2009) · Nature · doi:10.1038/nature07968 · Cited by 1,038
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804295105 · Cited by 995
Self-citationOncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Lenz, G., Davis, R. E., Ngo, V. N., Lam, L., George, T. C., Wright, G. W., Dave, S. S., Zhao, H., Xu, W., Rosenwald, A., et al. (2008) · Science · doi:10.1126/science.1153629 · Cited by 867
Self-citationStructural basis for signal transduction by the Toll/interleukin-1 receptor domains
Xu, Y., Tao, X., Shen, B., Horng, T., Medzhitov, R., Manley, J. L., & Tong, L. (2000) · Nature · doi:10.1038/35040600 · Cited by 818
A loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationFrequent inactivation of A20 in B-cell lymphomas
Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., Niwa, A., Chen, Y., Nakazaki, K., Nomoto, J., et al. (2009) · Nature · doi:10.1038/nature07969 · Cited by 555
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Self-citationStaudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Self-citationTNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Schmitz, R., Hansmann, M.-L., Bohle, V., Martin-Subero, J. I., Hartmann, S., Mechtersheimer, G., Klapper, W., Vater, I., Giefing, M., Gesk, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090528 · Cited by 481
Self-citationLam, L. T., Wright, G., Davis, R. E., Lenz, G., Farinha, P., Dang, L., Chan, J. W., Rosenwald, A., Gascoyne, R. D., & Staudt, L. M. (2008) · Blood · doi:10.1182/blood-2007-09-111948 · Cited by 353
Self-citationMilhollen, M. A., Traore, T., Adams-Duffy, J., Thomas, M. P., Berger, A. J., Dang, L., Dick, L. R., Garnsey, J. J., Koenig, E., Langston, S. P., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272567 · Cited by 323
Self-citationLam, L. T., Davis, R. E., Pierce, J., Hepperle, M. E., Xu, Y., Foley, M. H., Nong, Y., Wen, D., Adams, J., Dang, L., et al. (2005) · PubMed · Cited by 312
Self-citationDing, B. B., Yu, J. J., Yu, R. Y.-L., Mendez, L. M., Shaknovich, R., Zhang, Y., Cattoretti, G., & Ye, B. H. (2008) · Blood · doi:10.1182/blood-2007-04-087734 · Cited by 298
Yamin, T.-T., & Miller, D. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21540 · Cited by 281
Novak, U., Rinaldi, A., Kwee, I., Nandula, S. V., Rancoita, P. M. V., Compagno, M., Cerri, M., Rossi, D., Murty, V. V., Zucca, E., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174110 · Cited by 246
A library of gene expression signatures to illuminate normal and pathological lymphoid biology
Shaffer, A. L., Wright, G., Yang, L., Powell, J., Ngo, V., Lamy, L., Lam, L. T., Davis, R. E., & Staudt, L. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00373.x · Cited by 228
Self-citationInnate immune recognition of, and regulation by, DNA
ISHII, K., & AKIRA, S. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.09.002 · Cited by 224
Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases
Lam, J. S., Yamashiro, J., Shintaku, I. P., Vessella, R. L., Jenkins, R. B., Horvath, S., Said, J. W., & Reiter, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1842 · Cited by 211
Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis
Jiang, Z., Georgel, P., Li, C., Choe, J., Crozat, K., Rutschmann, S., Du, X., Bigby, T., Mudd, S., Sovath, S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603804103 · Cited by 139
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4
Powers, J. P., Li, S., Jaén, J. C., Liu, J., Walker, N. P. C., Wang, Z., & Wesche, H. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.020 · Cited by 118
Li, C., Zienkiewicz, J., & Hawiger, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503262200 · Cited by 118
New insights into the regulation of human B-cell differentiation
Schmidlin, H., Diehl, S. A., & Blom, B. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.03.008 · Cited by 100
Cited by
Toll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Genetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Self-citationChapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Self-citationThe history of toll-like receptors - redefining innate immunity
O'Neill, L. A. J., Golenbock, D., & Bowie, A. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3446 · Cited by 1,765
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Metadata
- Authors
- Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., Shaffer, A. L., Romesser, P., Wright, G., Powell, J., Rosenwald, A., Muller-Hermelink, H. K., Ott, G., Gascoyne, R. D., Connors, J. M., Rimsza, L. M., Campo, E., Jaffe, E. S., Delabie, J., Smeland, E. B., Fisher, R. I., Braziel, R. M., Tubbs, R. R., Cook, J. R., Weisenburger, D. D., Chan, W. C., & Staudt, L. M.
- Venue
- Nature
- Published
- 2010-12-22
- Volume
- 470
- Issue
- 7332
- Pages
- 115-119
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2116382435
- Cited by
- 1,512
- References
- 27
- FWCI
- 46.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.